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Abstract
Background: the mainstay of treatment of polymyalgia rheumatica (PMR) is oral glucocorticoids, but randomized
controlled trials of treatment are lacking. As a result, there is no evidence from controlled studies on the efficacy of
different initial doses or glucocorticoid tapering. The aim of this study is to test if 12.5 mg prednisone/day is an
adequate starting dose in PMR and to evaluate clinical predictors of drug response.
Methods: 60 consecutive PMR patients were treated with a starting dose of 12,5 mg/day prednisone. Clinical,
laboratory, and, in a subset of 25 patients, ultrasonographic features were recorded as possible predictors of
response to prednisone. Remission was defined as disappearance of at least 75% of the signs and symptoms of
PMR and normalization of ESR and CRP within the first month, a scenario allowing steroid tapering.
Results: 47/60 (78.3%) patients responded to 12.5 mg of prednisone after a mean interval of 6.6 ± 5.2 days. In
univariate analysis, body weight and gender discriminated the two groups. In multivariate analysis, the only factor
predicting a good response was low weight (p = 0.004); the higher response rate observed in women was
explained by their lower weight. The mean prednisone dose per kg in the responders was 0.19 ± 0.03 mg in
comparison with 0.16 ± 0.03 mg for non responders (p = 0.007).
Conclusions: 12.5 mg prednisone is a sufficient starting dose in ¾ of PMR patients. The main factor driving
response to prednisone in PMR was weight, a finding that could help in the clinical care of PMR patients and in
designing prospective studies of treatment.
Trial Registration: ClinicalTrials.gov: NCT01169597
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Background
Polymyalgia rheumatica (PMR) is a common inflamma-
tory condition affecting elderly people and involving the
girdles [1]. The mainstay of treatment is oral glucocorti-
coids (GC), with the recent BSR-BHPR guidelines sug-
gesting an initial prednisone dose comprised between 15
and 20 mg as appropriate [2]. However, probably
because of the dramatic response of PMR to GC, rando-
mized controlled trials of treatment are lacking. As a
result, there is no evidence from controlled studies on
the efficacy of different initial doses or drug tapering.
The only controlled study suggests that initial predni-
sone doses ≤ 10 mg is associated with high incidence of
recurrences, whereas doses ≥ 20 mg are associated with
considerable side effects [3]. Severe steroid toxicity is
frequent, occurring in 65% of the patients, and is asso-
ciated with duration of treatment and cumulative GC
dosage [4]. Up to 55% of PMR patients have relapsing
disease and require long-term steroid treatment. In one
descriptive study, the initial dose was linked to treat-
ment duration and cumulative dosage, for low initial
doses were associated with low subsequent maintenance
doses [5]. However, most studies are observational and
their results could be biased by confounding by indica-
tion, i.e. more severe patients being likely to receive
higher doses of GC. Identifying the correct starting dose
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avoid overtreatment and to reduce the occurrence of
side effects.
The aims of this study are (a) to test if 12.5 mg pre-
dnisone daily is an adequate starting dose in PMR and
(b) to evaluate the factors that could predict a positive
response to this initial dose.
Methods
Sixty consecutive patients with PMR, diagnosed accord-
ing to the criteria of Bird et al. [6] and visited in two
rheumatological tertiary referral centers (Universities of
Genova and Pavia, Italy), were considered. Enrolment
lasted one year and follow-up lasted one month. An
informal chart review was done after 6 month from
enrolment to assess the rate of exacerbations. There
were 25 men and 35 women; mean age was 71.4 ± 7.2
years. The study protocol was approved by the relevant
ethical committees. After written informed consent was
obtained, the following demographic and disease charac-
teristics were evaluated: age, sex, body weight measured
at the time of the first visit, duration of disease, pre-
sence of fatigue, fever, and weight loss, duration of
morning stiffness, presence of carpal tunnel syndrome,
RS3PE, peripheral arthritis or tenosynovitis. Standar-
dized clinical examination included the following: a) ten-
derness on palpation of bicipital tendon root, coracoid,
l e s s e ra n dg r e a t e rt u b e r o s i t ies, and posterior cuff; b)
pain worsened by passive and active mobilization, and
limitation of motion of the shoulder; c) pain in the
groin worsened by passive and active movements and
associated with positive Fabere’s test, suggesting coxofe-
moral synovitis; d) aching on the lateral aspect of the
hip and thigh, increased by external rotation and abduc-
tion and localized tenderness on palpation over the
greater trochanter, suggesting trochanteric bursitis; e)
tenderness aggravated by extension and relieved by flex-
ion of the hip, suggesting ileo-psoas bursitis; f) pain over
the ischions aggravated by sitting and lying, associated
with tenderness on palpation over the ischial tuberos-
ities, suggesting ischio-gluteal bursitis; g) paravertebral
tenderness and limitation of movement in the lumbar
and cervical spine. The two clinical assessors involved in
the study (MAC and RC) participated in two training
sessions to standardize clinical examination. Patients
were instructed to subjectively rate the intensity of fati-
gue and of the pain experienced during the visit on a
scale between 0 and 10. Laboratory and imaging investi-
gations included erythrocyte sedimentation rate (ESR),
C-reactive protein (CRP), IgM rheumatoid factor (RF)
and ultrasonography (US) of the shoulders. This last
examination was performed only in a subset of 25
patients. It included the evaluation of gleno-humeral
synovitis (hypoechoic or anechoic effusion larger than 2
mm when measured with a posterior approach and arm
in external rotation, or larger than 3.8 mm when mea-
sured in the axillary recess between bone and capsule),
long head biceps tenosynovitis (hypoechoic or anechoic
effusion of the tendon’s sheath with diameter larger
than 1.4 mm), and subacromial/subdeltoid bursitis
(hypoechoic or anechoic effusion with largest sagittal
diameter larger than 2 mm). All examinations were per-
formed at the time of the first visit; clinical examination
and parameters of inflammation were evaluated also at
1 and 4 weeks. All the patients were treated with 12.5
mg of prednisone daily in the early morning. For the
purpose of the study, patients with clinical and labora-
tory remission of PMR with the above reported dose of
prednisone, were considered responders. Remission was
defined as at least a 70% global improvement of the
signs and symptoms of PMR and normalization of ESR
and CRP within the first month, allowing steroid taper-
ing. Non-responders were patients who did not reach
remission and, as a consequence, needed an increase in
prednisone dosage in the first month of treatment. The
interval between treatment initiation and response to it
was recorded. The patients were instructed to record on
a diary their clinical status and the exact day in which
remission was achieved.
Means were compared by the Student’s t test or by
one way analysis of variance if their distribution was
normal and by the Kruskall Wallis test when it was non
parametrical. Frequencies were compared by Fischer’s
exact test. Changes in ESR and CRP during the study
period were evaluated between subjects and within sub-
jects by repeated measures ANOVA. A multiple regres-
sion model was also used with response to treatment as
dependent variable. All the calculations were performed
using Medcalc
® version 9.6.4.0 (Belgium) as statistical
software.
Results
In the 60 consecutive patients with PMR studied, the dis-
ease was newly diagnosed and had not been treated with
steroids before. The median interval between disease
onset and diagnosis was 90 days (range 18-720 days).
None of the patients had signs or symptoms suggestive
of temporal arteritis at the time of diagnosis or during
the observation period. 47/60 (78.3%) patients responded
t o1 2 . 5m go fp r e d n i s o n ew i t h i no n em o n t ha f t e rb e g i n -
ning therapy. In the responders, the mean interval
between initiation of treatment and clinical remission
was 6.6 ± 5.2 days (range 1-30 days) (figure 1). The uni-
variate analysis comparison between responders and
non-responders is reported in table 1. Only body weight
and gender discriminated the two groups of patients. In
multivariate analysis, the only factor predicting a good
response was a low weight (p = 0.004). The higher
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lower weight (63.2 ± 7.9 kg vs. 79.2 ± 12.4 kg, p < 0.001).
The mean prednisone dose per kg in the responders was
0.19 ± 0.03 mg in comparison with 0.16 ± 0.03 mg for
non-responders (p = 0.007). None of the features investi-
gated by physical examination could differentiate respon-
ders from non-responders (data not shown). US
examination was performed in 21 responders and 4 non-
responders. At US, the frequency of gleno-humeral syno-
vitis (p = 0.71), long head biceps tenosynovitis (p = 0.36),
and subacromial/subdeltoid bursitis (p = 0.91) was not
different in the 2 groups of patients. This was the case
also when bilateral involvement of the US pattern was
considered.
The changes of ESR and CRP during the study period
are reported in figure 2 and 3, respectively. There was a
significant decrease of inflammatory parameters both in
responders and non-responders. However, responders
had a more pronounced decrease than non-responders.
Of the 13 non-responders, 7 still had PMR signs and
symptoms, 5 has elevated ESR, and 3 elevated CRP, with
only one patient showing both elevated CRP and ESR.
Their dose of prednisone had been increased within one
month from initiation of therapy between 2.5 and 12.5
mg/day with a resulting mean dose of 21.1 ± 3.2 mg/
day. In this group, remission was reached after a mean
interval of 41.2 ± 21.8 days. After dose adjustment, their
mean prednisone dose per kg was 0.27 ± 0.06 mg. The
median dose per kg for the whole group was 0.20 mg
(range 0.13 mg-0.37 mg; 95% CI 0.19 mg-0.21 mg).
Figure 1 Interval between initiation of treatment and clinical remission.
Table 1 Comparison of demographic, clinical, and
laboratory results in PMR patients with or without
response to 12.5 mg daily of prednisone
FEATURE RESPONDERS NON RESPONDERS p
Number 47 (78.3%) 13 (21.7%)
Gender (women/men) 31/16 4/9 0.05
Age (years) 71.3 ± 7.1 71.5 ± 7.9 0.95
Weight (kg) 67.4 ± 11.4 78.5 ± 13.9 0.004
Disease duration (days) 90 (12-720) 86 (24-210) 0.32
Morning stiffness (minutes) 100.7 ± 85.9 89.0 ± 52.2 0.69
Fatigue 26 (55.3%) 10 (76.9%) 0.28
Fever 10 (21.3%) 3 (30%) 0.81
Weight loss 16 (34%) 2 (15.4%) 0.34
Peripheral arthritis 13 (27.7%) 4 (30.8%) 0.89
Carpal tunnel syndrome 16 (34.0%) 2 (15.4%) 0.34
RS3PE 8 (17.0%) 2 (15.4%) 0.78
Tenosynovitis 4 (8.5%) 1 (7.7%) 0.64
ESR (mm/h) 63.8 ± 25.8 62.5 ± 22.4 0.88
CRP (mg/L) 30 (1.5-180) 30 (2.5-247) 0.96
Figure 2 Erythrocyte sedimentation rate (ESR) at baseline and
at the week 1 and 4 control visits in the whole group of
patients, in responders and non-responders. There was a
significant difference by repeated measures ANOVA between
responders and non-responders (p = 0.017) and within groups (p <
0.001).
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from study initiation, 14/60 (23.3%) of the patients had had
one or more exacerbations. They occurred in 8/47 (17%)
responders and in 4/13 (30.8%) non-responders (p = 0.48).
Discussion
Our results support the hypothesis that a low initial
dose of prednisone is sufficient to control PMR in the
majority of patients. They also suggest that 0.20 mg
per kg weight could be the adequate starting dose,
although these data should be confirmed in prospective
studies in which steroid dose is adjusted to body
weight. It is possible that, due to the open design of
the study, a placebo effect increased the response rate
of our patients. However, since no comparison was
made between different treatments, we think it could
not have biased the results. Responders reached clini-
cal remission in 6.6 days in average; most of them
within 10 days from onset of therapy. This observation
suggests that a close follow-up in the first days after
diagnosis and treatment initiation is important to
ensure that the patient is administered an adequate
prednisone dosage.
There is only one comparison of two different dosages
of GC in the literature [7]: PMR patients were randomly
assigned to an initial regimen of 10 mg or 20 mg pre-
dnisolone and followed for two months. The patients on
the low dose GC regimen had a higher incidence of
relapses during the follow-up. The same incidence of
giant cell arteritis was seen in both groups. No attempt
was made to correlate efficacy with body weight in this
study. Conversely, an initial prednisolone dose of 10
mg/day was felt adequate by Behn et al. [8], with only
8/67 (11.9%) PMR patients needing an increase in
dosage. Another study used a standardized schedule of
p r e d n i s o n ew i t has t a r t i n gd o s eo f2 0m g / d a y[ 9 ] .
Twenty out of 27 patients (74%) reached remission with
this regimen, a percentage similar to that obtained in
our study with a much lower dose. This observation
suggested that there is a subset of a quarter of PMR
patients with steroid-resistant disease [9], regardless of
the initial GC dose utilized. Other observational studies
used initial GC mean doses comprised between 12.8 mg
[10] and 22.8 mg [11]. However, due to lack of clinical
information, it is impossible to derive from these papers
how effective was GC in the initial period of treatment.
Disease activity, evaluated by clinical, laboratory, and
ultrasonographic parameters, was not important to pre-
dict response to therapy. However, the power to test the
predictive value of US was probably low because of the
limited number of patients in whom the examination
was performed. In univariate analysis, women showed a
slightly better response to treatment than men. In con-
trast, previous data on PMR [12] and rheumatoid arthri-
tis [13] have reported higher disease severity and lower
rate of response to GC in women. In fact, when multi-
variate analysis was performed on our cases, the associa-
tion of female sex to response appeared spurious, being
related to the lower mean weight of women. The obser-
vation that the optimal starting dose depends on weight
and not on disease activity, and is relatively low, may
confirm the view that GC action in PMR is more of
replacement type than anti-inflammatory [14]. The
importance of body weight in the response to predni-
sone treatment is not surprising, in view of the fact that
GC have a high volume of distribution and are highly
lypophilic [15].
One of the limitations of this study is that clinical asses-
sors could not be blinded to patient’s weight. In addition,
the design of the study limited the follow up to only one
month. To partially overcome this last limitation, we per-
formed an informal chart review to assess the presence of
exacerbations within the first 6 months of treatment. Only
23% of the patients had one or more exacerbations with
no differences between initial responders and non-respon-
ders. As a result, the rate of exacerbations was low in com-
parison with other studies using similar [7] or higher
initial doses of GC [9,11] and response to a lower initial
dose of prednisone was not correlated with a higher inci-
dence of exacerbations. Although we cannot assume that a
low GC starting dose necessarily corresponds to a low
cumulative dosage, this is suggested by several observa-
tional studies [5].
Figure 3 C-reactive protein (CRP) at baseline and at the week 1
and 4 control visits in the whole group of patients, in
responders and non-responders. There was a significant
difference by repeated measures ANOVA between responders and
non-responders (p = 0.044) and within groups (p < 0.001).
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PMR in most studies [16], but the dose at which the
drug should be administered to the effect has not been
defined. An international group has recently addressed
this problem by consensus, with rapid response to ster-
oids defined as > 75% global response within 1 week to
15-20 mg daily of prednisone [17]. The BSR-BHPR
guidelines suggest the same [2], but there is only type C
evidence to support this view [18]. Our data could help
standardize the optimal starting dose. They suggest that,
in low-weight patients, this dose could be lower than
that previously suggested. In fact 78.3% of our patients
could benefit from a starting dose below 15 mg predni-
sone. This is in keeping with the EULAR recommenda-
tions to use the lowest possible GC dose in PMR [19].
The mean time interval needed to reach remission in
our cohort of responsive patients was similar to that
suggested by the panel of experts.
Conclusions
In conclusion, in our experience low dose GC was effec-
tive in the majority of PMR patients and the main factor
driving response to steroids in PMR was weight, a find-
ing that could help to manage the clinical care of PMR
patients and design prospective studies of treatment.
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